# US 2024/0189270 A1 · Methods and compositions for treating excessive sleepiness

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189270 A1
- Document ID: US20240189270A1
- Status: Published application
- Kind: A1
- Application number: 18/582,125
- Filed: 2024-02-20
- Published: 2024-06-13
- Earliest claimed: 2017-06-02
- Assignees: Axsome Malta Ltd.
- Applicants: Axsome Malta Ltd.
- Inventors: Lawrence Patrick CARTER; Yuan Lu; Katayoun Zomorodi
- Web page: https://patentgrep.com/patent/US20240189270A1

## CPC

- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders. The invention further relates to the development of methods for treating excessive sleepiness in a subject, e.g., due to narcolepsy or obstructive sleep apnea, with the surprising outcome that “normal” levels of wakefulness are achieved based on standard objective and subjective sleepiness tests.

## Claims

### Claim 1

A method for treating excessive daytime sleepiness in a subject in need thereof, comprising administering once daily to the subject a pharmaceutical composition comprising (R)-2-amino-3-phenylpropyl carbamate (APC) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered to the subject within 3 hours of the subject waking, and wherein the pharmaceutical composition is an immediate release compressed tablet, the tablet comprising:
APC or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
at least one binder in an amount of about 1-5% by weight of the tablet; and
at least one lubricant in an amount of about 0.1-2% by weight of the tablet;
wherein the tablet releases at least 85% of APC or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the tablet is administered to the subject within 1 hour of the subject waking.

### Claim 3 (depends on 1)

The method of claim 1, wherein the excessive daytime sleepiness is due to narcolepsy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the excessive daytime sleepiness is due to obstructive sleep apnea.

### Claim 5 (depends on 1)

The method of claim 1, wherein the excessive daytime sleepiness is due to shift work disorder.

### Claim 6 (depends on 1)

The method of claim 1, wherein the excessive daytime sleepiness is due to depresssion

### Claim 7 (depends on 1)

The method of claim 1, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 37.5 mg.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 75 mg.

### Claim 9 (depends on 1)

The method of claim 1, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 150 mg.

### Claim 10 (depends on 1)

The method of claim 1, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 300 mg.

### Claim 11

A method for minimizing insomnia while treating excessive daytime sleepiness in a subject in need thereof, comprising administering once daily to the subject a pharmaceutical composition comprising (R)-2-amino-3-phenylpropyl carbamate (APC) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered to the subject within 3 hours of the subject waking, and wherein the pharmaceutical composition is an immediate release compressed tablet, the tablet comprising:
APC or a pharmaceutically acceptable salt thereof in an amount of about 90-98% by weight of the tablet;
at least one binder in an amount of about 1-5% by weight of the tablet; and
at least one lubricant in an amount of about 0.1-2% by weight of the tablet;
wherein the tablet releases at least 85% of APC or a pharmaceutically acceptable salt thereof contained therein within a period of less than 15 minutes after administration of the tablet to the subject.

### Claim 12 (depends on 10)

The method of claim 10, wherein the tablet is administered to the subject within 1 hour of the subject waking.

### Claim 13 (depends on 11)

The method of claim 11, wherein the excessive daytime sleepiness is due to narcolepsy.

### Claim 14 (depends on 11)

The method of claim 11, wherein the excessive daytime sleepiness is due to obstructive sleep apnea.

### Claim 15 (depends on 11)

The method of claim 11, wherein the excessive daytime sleepiness is due to shift work disorder.

### Claim 16 (depends on 11)

The method of claim 11, wherein the excessive daytime sleepiness is due to depression.

### Claim 17 (depends on 11)

The method of claim 11, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 37.5 mg.

### Claim 18 (depends on 11)

The method of claim 11, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 75 mg.

### Claim 19 (depends on 11)

The method of claim 11, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 150 mg.

### Claim 20 (depends on 11)

The method of claim 11, wherein the tablet comprises APC or a pharmaceutically acceptable salt thereof at a dose of about 300 mg.
